Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center
Fatih Karbeyaz(University Hospital Zurich), Alexander Siebenhüner(University Hospital Zurich), Paul Julius Jaklin(University Hospital Zurich), Barbara Brunner(University Hospital Zurich), Benjamin Misselwitz(University of Zurich), Jaqueline Bachofner(University Hospital Zurich), Seraphina Kissling(University of Zurich), Stefanie von Felten(University of Zurich), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Thomas Winder, Beat Müllhaupt(University Hospital of Zurich)
Cited by 2
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
|Journal of Hepatology|2021|309